TriangleNCT00509041 · OUTCOME
Overall Survival
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- weeks
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- Time from registration to death (up to 3 years)
What was measured
Overall survival (OS) was defined as the time from registration to death of any cause. Surviving patients were censored at the date of last follow-up. The median OS with 95% CI was estimated using the Kaplan Meier method.
Groups in this outcome
Dasatinib
Use of dasatinib (50 mg orally twice a day) in treatment of pts with previously treated malignant mesothelioma
| Group | Source count |
|---|---|
| Dasatinib | 43 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Dasatinib | 26.1 | Not reported | 18.6 | 36.7 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 18.6
- upper Limit
- 36.7
- value
- 26.1
- denoms
- counts
- group Id
- OG000
- value
- 43
- units
- Participants
- description
- Overall survival (OS) was defined as the time from registration to death of any cause. Surviving patients were censored at the date of last follow-up. The median OS with 95% CI was estimated using the Kaplan Meier method.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Use of dasatinib (50 mg orally twice a day) in treatment of pts with previously treated malignant mesothelioma
- id
- OG000
- title
- Dasatinib
- param Type
- MEDIAN
- reporting Status
- POSTED
- time Frame
- Time from registration to death (up to 3 years)
- title
- Overall Survival
- type
- SECONDARY
- unit Of Measure
- weeks
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice